Business Wire

Lenovo Commits to Net-Zero Emissions by 2050, Validated by Science Based Targets initiative

19.1.2023 17:56:00 EET | Business Wire | Press release

Share

Today, Lenovo (HKSE: 992) (ADR: LNVGY) announced its goal to reach net-zero greenhouse gas (GHG) emissions by 2050, validated and approved by the Science Based Targets initiative (SBTi), a partnership between the UN Global Compact, CDP and World Wide Fund for Nature – making it the first PC and smartphone maker and one of only 139 companies in the world with a net-zero target validated by SBTi.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230119005499/en/

By working with SBTi and aligning to their Net-Zero Standard (the world’s first), Lenovo is taking a scientific, collaborative and accountable approach to reducing emissions.

“As a global technology leader, Lenovo has been committed to reducing its emissions for more than a decade,” said Lenovo Chairman Yuanqing Yang. “In the fight against climate change, we believe collaboration and accountability are the two critical elements needed for collective success. We remain dedicated to following climate science, standardizing our measurements, and seeking ongoing validation for our targets and progress.”

Aligning goals to the SBTi helps hold companies accountable for their emissions reduction. Without aligning to SBTi, it is difficult to validate or know when a net-zero target is reached. This is because:

  1. Standardization: SBTi is the first body to standardize what net-zero means as it relates to the effort to limit global warming to 1.5 degrees Celsius.
  2. Adaptation: SBTi’s standard is dynamic and responsive to companies’ collective effort and the changing temperature of the planet.
  3. Accountability: While 2050 seems far away for many, many leaders making commitments today may not be in their positions in 27 years. Aligning goals to reduce climate change to an external body provides accountability and continuity.

“Climate science tells us that we need rapid and deep emissions cuts if we are to achieve global net-zero and prevent the most damaging effects of climate change,” said Luiz Amaral, Chief Executive Officer of the Science Based Targets initiative. “Lenovo’s net-zero targets match the urgency of the climate crisis and set a clear example that their peers must follow.”

Lenovo’s long-term 2050 goals coincide with its near-term, SBTi-validated 2030 emissions reduction goals, all of which are outlined below:

Overall Net-Zero Target

Lenovo commits to reach net-zero GHG emissions across the value chain by FY2049/2050.

Near-Term Targets

Lenovo commits to reduce absolute scope 1 and scope 2 GHG emissions 50% by FY2029/2030 from a FY2018/2019 base year. Lenovo also commits to reduce scope 3 GHG emissions from use of sold products 35% on average for comparable products within the same timeframe. Lenovo commits to reduce scope 3 GHG emissions from purchased goods and services 66.5% per million US$ gross profit within the same timeframe. Lenovo further commits to reduce scope 3 GHG emissions from upstream transportation and distribution 25% per tonne-km of transported product by within the same timeframe.

Long-Term Targets

Lenovo commits to reduce absolute scope 1, 2, and 3 GHG emissions by 90% by FY2049/50 from a FY2018/19 base year.

Lenovo is an early adopter of the science-based emissions reduction approach, after receiving approval for near-term 2030 emissions reduction goals in 2020 and helping to road test the first of its kind Net-Zero Standard.

“Success in achieving net-zero depends on a transparent, science-based and collaborative framework that will keep organizations accountable for the long run. SBTi has created that framework and will empower companies to expedite emissions reduction,” commented Carolina Milanesi, Founder of The Heart of Tech, an ESG-focused consultancy.

Primary strategies for reducing Lenovo’s emissions include reducing the environmental impact of its products, harnessing innovation to increase sustainability in its manufacturing, and decreasing emissions across its operations and value chain. These strategies have been outlined in the company’s Journey to Net-Zero video series, which demonstrates how Lenovo’s experts are changing business processes to meet net-zero targets.

Lenovo’s emissions measurements will contribute to a wider body of collaborative data to understand and limit climate change, in accordance with the Paris Agreement’s goal to limit warming to no more than 1.5 degrees Celsius above pre-industrial levels. More than 4,000 companies around the world are in the process of aligning their emissions reduction goals to SBTi’s science-based methodology and validation processes.

In addition to its work to reduce emissions, Lenovo has been recognized in Gartner’s Top 25 Global Supply Chain, Fortune’s World’s Most Admired Companies, and as a leader in Climate Change and Water Security by CDP. Read more about Lenovo’s efforts to create a smarter, more sustainable future for all in the company’s FY 2021-22 ESG Report.

For more information visit Lenovo StoryHub.

About Lenovo

Lenovo (HKSE: 992) (ADR: LNVGY) is a US$70 billion revenue global technology powerhouse, ranked #171 in the Fortune Global 500, employing 82,000 people around the world, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver smarter technology for all, Lenovo has built on its success as the world’s largest PC company by further expanding into key growth areas including server, storage, mobile, solutions and services. This transformation together with Lenovo’s world-changing innovation is building a more inclusive, trustworthy, and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com,and read about the latest news via our StoryHub.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

sgill@lenovo.com
+44 (0)7917 437 532

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye